Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the paradigm of anticancer therapy in many cancer types, including advanced urothelial carcinoma (UC). Two anti-programmed death-1 (PD-1) monoclonal antibodies (pembrolizumab and nivolumab) and three anti-PD ligand-1 (PD-L1) monoclon...
Main Authors: | Jhe-Cyuan Guo, Yu-Chieh Tsai, Yeong-Shiau Pu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Urological Science |
Subjects: | |
Online Access: | http://www.e-urol-sci.com/article.asp?issn=1879-5226;year=2019;volume=30;issue=1;spage=2;epage=7;aulast=Guo |
Similar Items
-
Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
by: Hyung Suk Kim, et al.
Published: (2020-10-01) -
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
by: Yiming Wang, et al.
Published: (2018-03-01) -
Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01) -
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01) -
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
by: Kyu Sang Lee, et al.
Published: (2021-05-01)